Selank 10 mg is a lyophilized powder research peptide manufactured by Dragon Pharma, containing 10 mg of Selank (TKPRPGP) per 2 mL vial.
Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as an analogue of the endogenous immunomodulatory peptide tuftsin. Its amino acid sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), consisting of the native tuftsin tetrapeptide with a C-terminal Pro-Gly-Pro extension designed to enhance metabolic stability and prolong its duration of action.
In Russian clinical research, Selank has been studied for its anxiolytic, nootropic, and neuroprotective properties, which are reported to occur without the sedative and amnestic side effects associated with classical benzodiazepines. A 2015 randomized controlled trial compared phenazepam monotherapy to combined treatment with Selank and phenazepam in patients with anxiety disorders, finding that the combination reduced the level of undesirable side effects of phenazepam, including attention and memory impairment, asthenia, and sedation, while having a positive impact on patient quality of life.
Selank is not FDA-approved for any human use in the United States. It is approved only in the Russian Federation for generalized anxiety disorder and neurasthenia. As of April 2026, Selank is classified as an FDA Category 2 bulk drug substance, and compounding under Section 503A is restricted pending FDA review. In non-medical contexts, Selank is commonly referenced for its proposed anxiolytic and cognitive-enhancing effects, though such use falls outside approved indications.
Selank 10 mg is supplied as a lyophilized (freeze-dried) powder in a 2 mL vial. This form requires reconstitution with a suitable solvent such as bacteriostatic water before use.
Selank is a synthetic heptapeptide derived from the immunomodulatory tetrapeptide tuftsin, engineered for enhanced metabolic stability and a distinct neuropsychotropic activity profile.
Selank is a direct analogue of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide fragment of the heavy chain of human immunoglobulin G (IgG). The defining structural modification in Selank is the addition of a Pro-Gly-Pro tripeptide sequence at the C-terminus, which increases the peptide’s resistance to enzymatic degradation and prolongs its metabolic half-life compared to the naturally transient tuftsin.
Research on Selank’s mechanism of action indicates it functions as a positive allosteric modulator of GABA receptors. A 2018 study found that Selank affectsGABA binding and regulates GABA receptor activity in a specific manner that differs from benzodiazepines. The anxiolytic activity is proposed to be mediated by upregulation of GABAergic receptors and modulation of genes encoding enzymes responsible for GABA metabolism. Selank has also been shown to influence the balance of serotonergic and noradrenergic systems in the brain.
Published clinical trials are primarily from Russian institutions. A 2015 randomized controlled trial in patients with anxiety disorders found that combining Selank with phenazepam reduced the benzodiazepine’s side effects compared to phenazepam alone. No Western randomized controlled trials have been conducted, and the evidence base has not been independently replicated outside Russia.
Selank is approved in Russia for generalized anxiety disorder and neurasthenia. It is not FDA-approved for any indication, and no large-scale multicenter trials conforming to international regulatory standards have been published. The FDA has classified it as a Category 2 bulk drug substance, restricting compounding pending review.
Dragon Pharma offers several research peptides that are commonly referenced alongside Selank 10 mg in cognitive and anxiolytic contexts. Semax is a synthetic ACTH fragment studied for BDNF upregulation and cognitive stimulation, often stacked with Selank for combined anxiolytic and nootropic effects. DSIP is a delta sleep-inducing peptide investigated for sleep regulation and stress response. PE 22-28 is a TREK-1 channel blocker studied for rapid antidepressant-like effects through a distinct mechanism. These compounds act through different pathways than Selank’s GABAergic modulation.
Published laboratory reports for Selank 10 mg are shown below with the test date, measured concentration, and percentage of the product's 10 mg label claim.
View Report
Laboratory results apply to the specific tested sample represented in each published report and should not be interpreted as a measurement of every vial or production batch.
The information below is provided for educational reference only. Selank is not FDA-approved for any human use in the United States. All use in non-medical contexts falls outside approved indications.
Russian clinical trials have used intranasal Selank at doses of 250–300 mcg per administration, typically three times daily (750–900 mcg/day total). Community protocols generally align with this range, with most users starting at 200–300 mcg per day and titrating upward based on response. A 2017 study in rats used doses of 300 mcg/kg intraperitoneally.
| Use Case | Common Reference Range | Administration Frequency |
|---|---|---|
| Clinical (Russian trials) | 250–300 mcg per dose | 3 times daily |
| Community standard | 200–300 mcg per dose | 2–3 times daily |
| Community higher-dose | 600–900 mcg per day total | Split across 2–3 doses |
| Subcutaneous community | 250–500 mcg | Once daily |
Selank is most commonly stacked with Semax in community protocols, pairing Selank’s anxiolytic effects with Semax’s cognitive stimulation to produce a state of calm alertness. This combination is sometimes referenced for daytime focus and stress management. A less common stack pairs Selank with DSIP for combined anxiety and sleep support.
Community protocols widely adopt cycling patterns, commonly 4 weeks on followed by 4 weeks off, citing concerns about tolerance development. Russian clinical use does not emphasize cycling, but long-term continuous use data are limited. Bacteriostatic Water is commonly referenced for reconstitution.
Clinical data from Russian trials report that Selank is generally well-tolerated. A 2015 randomized controlled trial found that combining Selank with phenazepam reduced the benzodiazepine’s side effects, including attention and memory impairment, asthenia, sedation, and sexual disturbances. Mild nasal irritation has been noted with intranasal use.
No withdrawal, rebound, or dependence signature has been documented for Selank. However, the full side effect profile with extended human use is not characterized, and the absence of Western clinical trials limits confidence in the safety data.
Selank acts on GABAergic and monoaminergic systems rather than the hypothalamic-pituitary-gonadal axis. It does not suppress endogenous testosterone production, and post-cycle therapy in the context of testosterone recovery is not applicable.
Dosing strategies for Selank are based primarily on Russian clinical data and community reports. The information above is for educational reference and does not constitute medical advice.
Selank is not FDA-approved for any human use in the United States. It is approved only in the Russian Federation for generalized anxiety disorder and neurasthenia.
Selank is classified as an FDA Category 2 bulk drug substance, which restricts compounding under Section 503A pending FDA review. The safety and efficacy of Selank have not been established through adequate and well-controlled clinical trials meeting FDA standards. Available clinical data are drawn from Russian-language studies that have not been replicated in Western populations, and long-term safety data are not available.
Products labeled as Selank sold through online vendors without a prescription have received no FDA quality oversight and carry risks including incorrect concentration, contamination, and misidentified compound identity.
Selank is not FDA-approved for human use. Any use outside of approved research applications falls outside approved indications. Product concentration and laboratory verification do not establish that non-medical use is safe or appropriate for an individual.
Clinical data from Russian trials report that Selank is generally well-tolerated, with mild nasal irritation noted with intranasal use. Sedation is not a commonly reported effect, which distinguishes it from benzodiazepines in the available data.
Selank has cytokine-modulating activity, and the clinical significance of this effect in autoimmune contexts is unknown. The full side effect profile with extended human use is not characterized.
Known hypersensitivity to tuftsin or related peptides, concurrent benzodiazepine or other GABAergic therapy, pregnancy or breastfeeding (no reproductive or developmental data), active autoimmune conditions, and hepatic or renal impairment are considerations requiring medical evaluation before use.
GABAergic activity may interact with benzodiazepines and other CNS depressants, and the cytokine-modulating effects of Selank are of unknown clinical significance in autoimmune contexts.
No specific bloodwork monitoring is required for Selank based on available data. It is non-hormonal, non-hepatotoxic, and does not affect lipids, HPTA, prolactin, or metabolic markers. In non-medical contexts, individuals commonly reference standard health monitoring rather than Selank-specific testing.
No published laboratory reports are available for this specific product beyond the potency verification shown in the Lab Reports tab. That testing applies to the tested sample only and is separate from any clinical monitoring of the individual.
Lyophilized Selank should be stored tightly sealed in its original container, protected from light, and desiccated at -20°C for long-term storage. After reconstitution, store refrigerated at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles.
Keep all peptides and injectable products out of the reach of children. Follow the storage instructions provided with the product packaging.
Selank 10 mg by Dragon Pharma is supplied through the official distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Dragon Pharma distribution chain.
To verify your Selank 10 mg product, use the security code on the vial label and cross-check it on the Dragon Pharma official site. Official presentation, batch-linked lab proof, and original packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve peptide stability and overall product integrity throughout shelf life.
Store the lyophilized (dry) powder tightly sealed in its original container, protected from light, and desiccated at -20°C for long-term storage. Brief handling at refrigerated or ambient conditions is acceptable provided the container is allowed to equilibrate to room temperature before opening to prevent moisture uptake.
After reconstitution, store refrigerated at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles.
Keep out of reach of children. Follow proper handling and sterile technique when administering the product.
Answers to common questions about Selank 10 mg, its mechanism, product strength, and laboratory testing.
Selank 10 mg contains a tuftsin-derived heptapeptide. In Russian clinical research, it is studied for anxiolytic and nootropic effects without benzodiazepine-associated sedation. It is not FDA-approved for any human use, and all non-medical use falls outside approved indications.
Russian clinical trials have used intranasal Selank at 250–300 mcg per administration, three times daily. Community protocols commonly reference 200–300 mcg per dose, two to three times daily, with cycling patterns of 4 weeks on followed by 4 weeks off.
No. Selank acts on GABAergic and monoaminergic systems rather than the hypothalamic-pituitary-gonadal axis. It does not suppress endogenous testosterone production, and post-cycle therapy in the context of testosterone recovery is not applicable.
Selank is proposed to function as a positive allosteric modulator of GABA receptors, regulating GABA receptor activity in a manner distinct from benzodiazepines. It also influences serotonergic and noradrenergic systems. Clinical data from Russian trials support anxiolytic and cognitive-enhancing effects.
Intranasal Selank has a subjective onset of 10–20 minutes, with peak effect around 30–60 minutes and duration of 4–6 hours per dose. For tonic anxiolytic effects, 5–7 days of consistent dosing may be required before the full effect is apparent.
There is no evidence-based “best” anxiolytic peptide. Selank is studied for GABAergic modulation without sedation, while Semax is investigated for BDNF upregulation and cognitive stimulation. The two are often stacked for combined effects. The appropriate choice depends on individual goals.
Selank is a tuftsin-derived heptapeptide studied for anxiolytic effects through GABAergic modulation, while Semax is a synthetic ACTH fragment studied for cognitive enhancement through BDNF upregulation. They are often stacked together to produce a state of calm alertness.
Selank is studied for daytime anxiolytic effects through GABAergic modulation, while DSIP is a delta sleep-inducing peptide investigated for sleep regulation and stress response. Selank is sometimes stacked with DSIP for combined anxiety and sleep support.
300 mcg is within the range used in Russian clinical trials, which administered 250–300 mcg per dose three times daily. Community protocols commonly reference similar per-dose amounts, with total daily doses typically ranging from 200–900 mcg.
Selank 10 mg is labeled at 10 mg of Selank (TKPRPGP) per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before use.
Yes. A published laboratory report dated November 20, 2023 measured Selank 10 mg at 9.74 mg, equivalent to 97.4% of its 10 mg label claim. The batch number for this report is #HDSLK923.
The complete report can be viewed in the Lab Reports tab. Laboratory results apply to the tested sample represented by the individual report and should not be interpreted as a measurement of every vial.
Lyophilized Selank is typically reconstituted with a suitable solvent such as Bacteriostatic Water or sterile water. The volume of solvent added determines the concentration of the resulting solution. Proper sterile technique should be used during reconstitution.